Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.

Antimicrobial agents and chemotherapy - 1 Dec 2014

Eltahla Auda A, Tay Enoch, Douglas Mark W, White Peter A

Abstract excerpt

Direct-acting antivirals (DAAs) targeting proteins encoded by the hepatitis C virus (HCV) genome have great potential for the treatment of HCV infections. However, the efficacy of DAAs designed to target genotype 1 (G1) HCV against non-G1 viruses has not been characterized fully. In this study, we investigated the inhibitory activities of nonnucleoside inhibitors (NNIs) against the HCV RNA-dependent RNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzofurans
Share to Cyclohexanols
Share to Purines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridazines

Share to Pyrones

Share to Replicon

Share to Thiophenes

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 25246395
DOI: 10.1128/AAC.03699-14
PMCID: PMC4249545

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.PMID 25246395Read ↗

The RdRp Thumb-1 Pocket is a Conserved Target for Broad-Spectrum Antiviral DevelopmentSemantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Semantic proximity Read ↗

Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.Semantic proximity Read ↗

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.Semantic proximity Read ↗

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.Semantic proximity Read ↗

Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.Semantic proximity Read ↗

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.